Journal of Allergy and Clinical Immunology: Global (Nov 2023)

A pilot randomized clinical trial of γ-tocopherol supplementation on wood smoke–induced neutrophilic and eosinophilic airway inflammation

  • David B. Peden, MD,
  • Martha Almond, RRT,
  • Christian Brooks, BS,
  • Carole Robinette, MS,
  • Heather Wells, MS,
  • Allison Burbank, MD,
  • Michelle Hernandez, MD,
  • Alan Hinderliter, MD,
  • Melissa Caughey, PhD,
  • Qing Jiang, PhD,
  • Qianyue Wang, MS,
  • Haolin Li, BSPH,
  • Haibo Zhou, PhD,
  • Neil Alexis, PhD

Journal volume & issue
Vol. 2, no. 4
p. 100177

Abstract

Read online

Background: Air pollutants, including particulates from wood smoke, are a significant cause of exacerbation of lung disease. γ-Tocopherol is an anti-inflammatory isoform of vitamin E that has been shown to reduce allergen-, ozone-, and endotoxin-induced inflammation. Objective: The objective of this study was to determine whether γ-tocopherol would prevent experimental wood smoke–induced airway inflammation in humans. Methods: This was a randomized, placebo-controlled clinical trial testing the effect of a short course of γ-tocopherol–enriched supplementation on airway inflammation following a controlled exposure to wood smoke particulates. Results: Short-course γ-tocopherol intervention did not reduce wood smoke–induced neutrophilic airway inflammation, but it did prevent wood smoke–induced eosinophilic airway inflammation. Conclusion: γ-Tocopherol is a potential intervention for exacerbation of allergic airway inflammation, but further study examining longer dosing periods is required.

Keywords